Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
114.7 USD | +7.42% | +12.73% | -17.61% |
Jun. 06 | TD Cowen Adjusts Price Target on Illumina to $122 From $140 | MT |
Jun. 05 | Nephron Research Upgrades Illumina to Hold, Price Target at $100 | MT |
Business Summary
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Number of employees: 10,615
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Core Illumina
98.5
%
| 4,553 | 99.3 % | 4,438 | 98.5 % | -2.53% |
Grail
2.1
%
| 55 | 1.2 % | 93 | 2.1 % | +69.09% |
Eliminations
-0.6
%
| -24 | -0.5 % | -27 | -0.6 % | +12.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
52.4
%
| 2,290 | 50.0 % | 2,359 | 52.4 % | +3.01% |
Europe
25.3
%
| - | - | 1,140 | 25.3 % | - |
Asia-Pacific, Middle East and Africa
10.2
%
| 418 | 9.1 % | 459 | 10.2 % | +9.81% |
Greater China
8.5
%
| 472 | 10.3 % | 384 | 8.5 % | -18.64% |
Americas
3.6
%
| 189 | 4.1 % | 162 | 3.6 % | -14.29% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jacob Thaysen
CEO | Chief Executive Officer | 49 | 23-09-24 |
Steven Barnard
CTO | Chief Tech/Sci/R&D Officer | - | 97-12-31 |
Carissa Rollins
CTO | Chief Tech/Sci/R&D Officer | 54 | 22-03-13 |
Kevin Pegels
COO | Chief Operating Officer | 57 | 21-10-31 |
Investor Relations Contact | - | 21-11-30 | |
Bryan Crane
PRN | Corporate Officer/Principal | - | - |
Scott Ericksen
AUD | Comptroller/Controller/Auditor | 52 | 13-10-31 |
Bas Verhoef
PRN | Corporate Officer/Principal | - | Jan. 04 |
Charles Dadswell
LAW | General Counsel | 65 | 13-04-21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 58 | 12-11-28 |
Chairman | 60 | 23-06-01 | |
Caroline Dorsa
BRD | Director/Board Member | 64 | 17-01-26 |
Scott Ullem
BRD | Director/Board Member | 57 | 23-06-01 |
Philip Schiller
BRD | Director/Board Member | 63 | 16-07-27 |
Gary Guthart
BRD | Director/Board Member | 58 | 17-11-30 |
Scott Gottlieb
BRD | Director/Board Member | 51 | 20-02-03 |
Susan Siegel
BRD | Director/Board Member | 63 | 19-02-04 |
Frances Arnold
BRD | Director/Board Member | 67 | 16-01-27 |
Jacob Thaysen
CEO | Chief Executive Officer | 49 | 23-09-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 199,300,000 | 158,869,731 ( 79.71 %) | 40,000,000 ( 20.07 %) | 79.71 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Illumina Singapore Pte Ltd.
| |
Illumina Cambridge Ltd.
Illumina Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services Illumina Cambridge Ltd. develops, manufactures and commercializes instruments, consumables and technologies for the analysis of DNA and genetic variation. The company was founded in 1998 and is headquartered in Saffron Walden, the United Kingdom. |
Miscellaneous Commercial Services
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.61% | 17.01B | |
+9.24% | 220B | |
+15.84% | 198B | |
+23.95% | 148B | |
+31.67% | 112B | |
+4.68% | 66.17B | |
+14.99% | 52.47B | |
+4.85% | 50.77B | |
-4.47% | 38.97B | |
-0.41% | 35.13B |
- Stock Market
- Equities
- ILMN Stock
- Company Illumina, Inc.